H.S. and J.R.A. contributed equally to this work.
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
Version of Record online: 20 DEC 2013
© 2013 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Clinical & Experimental Allergy
Volume 44, Issue 1, pages 38–46, January 2014
How to Cite
Clinical & Experimental Allergy, 2014 (44) 38–46., , , , , , , , and ,
- Issue online: 20 DEC 2013
- Version of Record online: 20 DEC 2013
- Accepted manuscript online: 17 OCT 2013 02:34AM EST
- Manuscript Accepted: 10 OCT 2013
- Manuscript Revised: 7 OCT 2013
- Manuscript Received: 17 OCT 2012
|cea12220-sup-0001-FigS1-S5-TableS1.doc||Word document||1174K||Data S1. Methods.|
|cea12220-sup-0002-FigS1.tif||image/tif||59K||Figure S1. Study patient flowchart.|
|cea12220-sup-0003-FigS2.tif||image/tif||1840K||Figure S2. Late allergen response AUC FEV1 at Week 13 for each subject plotted by site.|
|cea12220-sup-0004-FigS3.tif||image/tif||66K||Figure S3. Serum concentration–time profile of lebrikizumab.|
|cea12220-sup-0004-FigS4.tif||image/tif||156K||Figure S4. Serum levels of IgE, CCL13, and CCL17 and relationship between predose levels of serum IgE, CCL13, and CCL17 with magnitude of effect.|
|cea12220-sup-0005-FigS5.tiff||TIFF image||323K||Figure S5. Serum levels of periostin, CEA, and YKL-40.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.